# Study on the Effect of Ibrutinib on High Risk Smoldering Multiple Myeloma Patients

> **NCT02943473** · PHASE2 · TERMINATED · sponsor: **Icahn School of Medicine at Mount Sinai** · enrollment: 9 (actual)

## Conditions studied

- High Risk Smoldering Multiple Myeloma

## Interventions

- **DRUG:** Ibrutinib

## Key facts

- **NCT ID:** NCT02943473
- **Lead sponsor:** Icahn School of Medicine at Mount Sinai
- **Sponsor class:** OTHER
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** TERMINATED
- **Start date:** 2017-05-18
- **Primary completion:** 2019-09-10
- **Final completion:** 2019-09-10
- **Target enrollment:** 9 (ACTUAL)
- **Why stopped:** Poor accrual and risk/benefit ratio.
- **Last updated:** 2020-12-16

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT02943473

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT02943473, "Study on the Effect of Ibrutinib on High Risk Smoldering Multiple Myeloma Patients". Retrieved via AI Analytics 2026-06-09 from https://api.ai-analytics.org/clinical/NCT02943473. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*